Dr. Reddy's Laboratories Ltd. (DRREDDY.NS)
-NSE 2,051.45 
4.30(0.21%) 5:59AM EDT
| Prev Close: | 2,055.75 |
|---|
| Open: | 2,060.75 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 2,217.15 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2,033.00 - 2,074.05 |
|---|
| 52wk Range: | 1,526.40 - 2,152.00 |
|---|
| Volume: | 399,910 |
|---|
| Avg Vol (3m): | 317,697 |
|---|
| Market Cap: | 348.42B |
|---|
| P/E (ttm): | 20.84 |
|---|
| EPS (ttm): | 98.44 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in INR.
Headlines
- Q4 2013 Dr. Reddy's Laboratories Earnings Release - Time Not SuppliedCCBN(Tue, May 14)
- India's NSE index hits 28-month highat Reuters(Sat, May 11)
- India's top generic drugmakers look to US as patents endat Reuters(Wed, May 8)
- Indian shares gain for fourth day as rate-cut hopes continue to aidat Reuters(Thu, Apr 25)
- Indian shares hit 4-month closing low; banks, technology fallat Reuters(Thu, Apr 4)
- UPDATE 1-Indian shares post biggest gain in 3 months on rate cut hopesat Reuters(Tue, Mar 5)
- Indian shares post biggest gain in 3 months on rate cut hopesat Reuters(Tue, Mar 5)
- UPDATE 1-India's Ranbaxy surprises with Q4 loss, sees modest sales growth in 2013at Reuters(Tue, Feb 26)
- India's Dr. Reddy's Q3 net falls 29 pct, lags forecastat Reuters(Thu, Feb 14)
Reports
- No Reports available for DRREDDY.NS at this time.
Key Statistics
| Forward P/E (1 yr): | 16.32 |
|---|
| P/S (ttm): | 3.00 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Mar-14)
: | 110.07 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 31.83 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | 1.09 |
|---|
Business Summary
Dr. Reddys Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products.
View More